GALAXY ENT (00027) announced its annual results for the period ending December 31, 2025. The group's full-year net revenue reached HK$49.2 billion, representing a 13% increase compared to the previous year. Adjusted EBITDA rose by 19% year-on-year to HK$14.5 billion. Profit attributable to shareholders amounted to HK$10.7 billion, up 22% from the prior year, with basic earnings per share of HK$2.44.

The company has been actively collaborating with the Macao Tourism Office to position Macao as a preferred travel destination, particularly within Asia. GALAXY ENT remains committed to advancing this initiative through its marketing teams and international offices in Seoul, Tokyo, Bangkok, and Singapore.

In terms of operational performance, the company continues to drive growth across its business segments, with a strategic focus on the premium mass and ultra-premium mass markets. The Capella brand began trial operations in May 2025 and officially opened on February 10, 2026. With its exceptionally luxurious suite offerings, Capella enables the company to more effectively capture market share in the ultra-premium mass segment on a larger scale, further strengthening its leadership in this high-value market.

Financially, GALAXY ENT’s adjusted EBITDA for 2025 increased by 19%, rising from HK$12.2 billion to HK$14.5 billion. Full-year profit attributable to shareholders grew by 22% to HK$10.7 billion. The company maintains a robust and highly liquid balance sheet, with cash and liquid investments totaling HK$36.3 billion. Supported by solid financial strength and healthy operating cash flow, GALAXY ENT is well-positioned to return capital to shareholders, fund development projects, pursue overseas expansion opportunities, and ensure a strong balance sheet even amid unforeseen economic challenges.

During 2025, the company distributed dividends twice, amounting to HK$0.50 and HK$0.70 per share respectively, totaling HK$1.20 per share for the year. Today, the board of directors has proposed a final dividend of HK$0.80 per share. These dividend payments reflect the company's continued confidence in the long-term prospects of both Macao and GALAXY ENT.